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Ras association domain family 1A (RASSF1A) is one of the most epigenetically silenced elements in human cancers. Localized
on chromosome 3, it has been demonstrated to be a bone ﬁde tumor suppressor inﬂuencing cell cycle events, microtubule
stability, apoptosis, and autophagy. Although it is epigenetically silenced by promoter-speciﬁc methylation in cancers, several
somatic nucleotide changes (polymorphisms) have been identiﬁed in RASSF1A in tissues from cancer patients. We speculate that
both nucleotide changes and epigenetic silencing result in loss of the RASSF1A tumor suppressor function and the appearance of
enhanced growth. This paper will summarize what is known about the origin of these polymorphisms and how they have helped
us understand the biological role of RASSF1A.
1.Introduction
Cancer is a disease aﬀecting 1 in 3 adults worldwide and
is considered to be the second leading cause of death in
both Canada and the United States behind heart disease
[1, 2]. It is thought that cancer arises due to the occurrence
of 2–5 genetic events to potentiate tumor formation and
sustain abnormal growth [3] .T h e s eg e n e t i cc h a n g e so c c u r
in passenger genes (to support the cancer phenotype) and
driver genes (to promote the cancer phenotype) [4]. About
10% of driver genes code for oncogenes that promote
accelerated growth. However, about 90% of the driver genes
code for tumor suppressor genes that inhibit accelerated
growth [3], suggesting that tumor suppressor genes play
an integral part in the origin of cancer. Evidence also
suggeststhatthemutationrateoftumorsuppressorgenesare
much higher than oncogenes supporting their importance in
cancer formation [3, 5].
In 2000, Hanahan and Weinberg systematicallydescribed
several key features or “hallmarks” of cancer that deﬁned
the behavior of a cancer cell [6]. These deﬁning features
of a cancer cell included the unique properties of limitless
replicative potential, evasion of apoptosis, ability to stimu-
late neo-vascularization, invasion and metastasis, inhibition
of suppressor pathways, and sustained proliferation. As
described in their seminal paper, the aforementioned hall-
marks are acquired through a “multistep process” that allows
the cancer cells to acquire key survival traits while avoiding
the watchful eye of established molecular “checkpoints” to
inhibit abnormal growth [7]. It was around this time that the
RASSF1 was identiﬁed as a potential tumor suppressor gene
onchromosome3,at3p21.23[8,9].Nowmorethanadecade
later, RASSF1A has been demonstrated using numerous
approaches to be a tumor suppressor gene and an important
driver gene in cancer inﬂuencing/intersecting with many of
the hallmarks of cancer [8, 10]. It is epigenetically silenced
in the majority of cancers by promoter speciﬁc methylation,
resulting in loss of expression of the RASSF1A protein
[11]. Although expression loss of RASSF1A by methylation
occurs frequently in cancer, nucleotide changes by somatic
mechanisms have also been detected in patients from several
cancer subtypes. Several studies have tried to elucidate the
importance of these polymorphic changes and how it may
aﬀect the tumor suppressor function of RASSF1A. They2 Molecular Biology International
have also revealed interesting and surprising inﬂuences on
numerous aspects of biology.
2. The Originof RASSF1APolymorphisms
The RASSF1 gene consists of eight exons alternatively spliced
to produce 8 isoforms, RASSF1A-H, that have distinct
functional domains including the Ras association (RA)
domain [9, 14]. Of these, RASSF1A and RASSF1C are the
predominant ubiquitously expressed forms in normal tissues
[9, 11]. RASSF1C has been demonstrated to be perinuclear
in appearance in NCI H1299 lung cancer cells [15], nuclear
in HeLa cells with translocation to the cytosol upon DNA
damage [16], and localized to microtubules in a similar
fashion to RASSF1A in 293T cells [17, 18]. Thus, the
localization of RASSF1C is varied and controversial. This is
not the case for RASSF1A as it has been demonstrated by our
group and several others to be a microtubule binding protein
having a microtubule like localization and functioning to
stabilize tubulin in a taxol like manner [13, 18, 19]. To date,
a crystal structure for RASSF1A or RASSF1C has not been
identiﬁed,butFoleyetal.[20]providedamolecularmodelof
theN-terminalC1domaincontainingfourzincﬁngermotifs
which is very similar to the one found on RASSF5A/Nore1A
[21]. The zinc ﬁnger motifs have now been demonstrated
to be involved in death receptor associations and possible
associations with other receptors or signaling components
[20]. In addition to the C1 domain, RASSF1A has been
noted to have a sequence speciﬁcity motifs to associate with
SH3 domain (PxxP); motifs for 14-3-3 associations; a Ras
association (RA) domain (although association is weak or
indirect for K-Ras) [10]; associations with the anaphase
promotingcomplexproteincdc20andtheautophagyprotein
C19ORF5/MAP1S; and heterotrophic associations with the
Hippo proapoptotic kinase (MST1/2) and the BH3-like
protein modulator of apoptosis 1 (MOAP-1) through the
Salvador/RASSF/Hippo (SARAH) domain (both reviewed
elsewhere in this issue) (please see Figure 1 for schematic
summary of RASSF1A protein associations).
RASSF1A polymorphisms have been identiﬁed in
several cancers as listed in Table 1 and can be mapped
to speciﬁc protein interaction domains (Figure 1). These
polymorphisms have been found in tumors from numerous
cancer patients and cell lines [22]. The population distribu-
tion and signiﬁcance of these alterations in tumorigenesis
remain to be determined but do vary from 9% to 33%
of the speciﬁc cancer population. The majority of
RASSF1A polymorphisms have been conﬁrmed using
several approaches as outlined by the 1000Genome
project (http://www.1000genomes.org/), HapMap project
(http://hapmap.ncbi.nlm.nih.gov/) and submitted by mul-
tiple sources (Table 1 and NCBI SNP database [http://
www.ncbi.nlm.nih.gov/projects/SNP/snp ref.cgi?showRare=
on&chooseRs=coding&go=Go&locusId=11186]andUniver-
sity of Maryland SNP database [http://bioinf.umbc.edu/
dmdm/gene prot page.php?search type=gene&id=11186,
NP 009113]). Recently, a comprehensive study of 400 lung,
renal, breast, cervical, and ovarian cancers by Kashuba
et al. [22]r e v e a l e df r e q u e n tl o s so fg e n e t i cm a t e r i a lo n
chromosome 3p in 90% of the tumors investigated.
Furthermore, they determined that the mutation rate in
cancer for RASSF1A was 0.42 mutation frequency/100 base
pair whereas in the “normal” population was about 0.10
mutations/100 base pairs. They speculate that RASSF1A has
a 73% GC content within exons 1–2 which may explain the
high mutation rate of RASSF1A within cancer cells. Within
cell lines, RASSF1A was found to carry 0.7 mutations/100bp
in the Burkitt’s lymphoma-derived cell lines, BL2 and
RAMOS, whereas it was 0.14 in the renal carcinoma cell
line KRC/Y and, with each division of the BL2 lymphoma
line, transitional mutations were observed. Interestingly,
codon changes in RASSF1A were also observed in 15 normal
human hearts that included two nucleotide changes (CTA
to CTG and GTA to GTG) but no amino acid changes [22].
They speculate that RASSF is simply located in an area
that is “extensively damaged” and susceptible to mutational
pressures in 90% of epithelial cancers [22].
The most common polymorphism is the alanine (A) to
serine (S) at amino acid 133 (A133S) located within the
ATM DNA damage checkpoint kinase site (please see below
sections).Thishasbeenidentiﬁedasasinglenucleotidegerm
line polymorphism (SNP) on both alleles in some breast
cancer patients and is signiﬁcantly associated with BRAC1/2
mutations. Patients with wild-type BRAC1/2 and RASSF1A
A133S have a +15-year better survival period than those
harboring both BRAC1/2 mutations and RASSF1A A133S
[23, 29]. The RASSF1A A133S SNP has been found in 20.6%
of patients with breast carcinomas [23, 29], 19.8% in lung
cancer [29, 32], 11.1% in head and neck cancer [32], 6.9%
in colorectal cancer [32], 14.3% in esophageal cancer [32],
24.3% in patients with ﬁbroadenoma and in 2.9%–10%
of healthy controls [23, 32]. Interestingly, Gao et al. [29]
also revealed the presence of the A133S polymorphism in
brain and kidney cancer patients and Bergqvist et al. (2010)
detectedthepresenceoftheA133SSNPin18.4%ofthewhite
British female population [28]. The high percent obtained
for the latter is surprising and requires further validation.
The prevalence of the rest of the RASSF1A polymorphisms
has not been determined yet, and functional studies to
systematically determine inﬂuence of these polymorphisms
onRASSF1Abiologicalfunctionareyettobedone.However,
in this paper we will only summarize what has been carried
out already to ascertain the consequences of polymorphisms
to RASSF1.
3.RASSF1A:A KeyElement inCellularStability
One of the most striking features of RASSF1A is its micro-
tubule appearance. Numerous tagged versions of RASSF1A
have all revealed similar microtubule-like appearance as seen
in MCF-7 breast cancer cells in Figure 2. This appearance
has been observed in many other cell lines with similar
appearances. It has also been determined that both N-
and C-terminal residues of RASSF1A are required for the
microtubuleappearanceofRASSF1A[13,18].Severalgroups
have characterized the appearance and function of the
microtubule localization of RASSF1A. It has been demon-
strated that the microtubule localization of RASSF1A mainlyMolecular Biology International 3
Table 1: RASSF1A single nucleotide polymorphisms. Several RASSF1A polymorphic changes have been identiﬁed as outlined in
Table 1. SNP sites consulted to draft this table include NCBI (at http://www.ncbi.nlm.nih.gov/projects/SNP/snp ref.cgi?showRare=on&
chooseRs=coding&go=Go&locusId=11186) and DMDM (at http://bioinf.umbc.edu/dmdm/gene prot page.php?search type=gene&id=
11186).
Polymorphism Tissue or cell line origin SNP ID% and other
information References
K21Q (AAG →CAG)
Breast (tumor)
Kidney (renal carcinoma cell TK10 and
KRC/Y)
Lung (Non small cell Lung cancer cell line)
rs4688725∗,∗∗,#,
Schagdarsurengin et al.
[23]; Dammann et al. [24];
Agathanggelou et al. [25];
Burbee et al. [26]
R28H (CGT → CAT) Breast (Tumor)
Lung (nonsmall cell lung cancer cell line)
Presence in lung carcinomas
are rare
Schagdarsurengin et al.
[23]; Dammann et al. [24];
Burbee et al. [26]
V47F (GTC → TTC) Not listed rs61758759∗,∗∗,#, NCB1%
R53C (CGC →TGC) Breast (tumor)
Lung (nonsmall cell lung cancer cell line) Q9NS23$
Schagdarsurengin et al.
[23]; Dammann et al. [24];
Burbee et al. [26]
A60T (GCA → ACA) Breast No SNP ID found Agathanggelou et al. [25]
C65R (TGC → CGT) Breast (tumor) No SNP ID found Dallol et al. [27]
S131F (TCT → TTT) Breast (tumor)
Kidney (Wilm’s tumor) No SNP ID found Schagdarsurengin et al.
[23]; Dammann et al. [24]
A133S (GCT → TCT)
Breast (tumor, ﬁbroademonas), 33%
Kidney (Wilm’s tumor), 21%
Brain (medulloblastoma), 9%
Muscle (rhadomyosarcoma), 19%
Lung (nonsmall cell lung cancer cell line)
rs52807901 and rs2073498
Association with BRAC1/2
mutations
Homozygous in breast cancer
21% of kids with germ line
mutation, maternal in origin
Schagdarsurengin et al.
[23]; Dammann et al. [24];
B e r g q v i s te ta l .[ 28]; Gao et
al. [29]; Burbee et al. [26];
Lusher et al. [30]
I135T (ATT →ACT) Lung (nonsmall cell lung cancer cell line)
Breast (tumor cell line) No SNP ID found Dammann et al. [24];
Agathanggelou et al. [25]
V211A (GTC → GCC) Breast No SNP ID found Agathanggelou et al. [25]
R201H (CGC → CAC) ENT (nasopharyngeal carcinoma)
In 23 tumor samples, 34 other
polymorphisms were detected
(not listed in this table) with
30 transitions, 2 transversions,
and 2 deletions (6 in SH3/C1
domain and 6 in RA domain)
Zhi-Gang Pan et al. [31]
E246K (GAA → AAG) Breast (tumor) No SNP ID found Agathanggelou et al. [25]
R257Q (CGG → CAG) Breast (Tumor)
Lung (nonsmall cell lung cancer cell line No SNP ID found
Schagdarsurengin et al
[23]; Dammann et al. [24];
Agathanggelou et al. [25];
Dallol et al. [27]
H315R (CAC → CGC) NCBI SNP database, source unknown rs52792349 and rs12488879 Geoﬀery Clark (personnel
communication)
Y325C (TAT → TGT) Breast (tumor)
Lung (nonsmall cell lung cancer cell line No SNP ID found
Schagdarsurengin et al.
[23]; Dammann et al. [24];
Burbee et al. [26]
L270V (CTG → GTG) Cervical (tumor) No SNP ID found Schagdarsurengin et al.
[23]; Dammann et al. [24]
A336T (GCC → ACC) Lung (nonsmall cell lung cancer cell line No SNP ID found Dammann et al. [24]
%http://bioinf.umbc.edu/dmdm/gene prot page.php?search type=gene&id=11186.
$UniProtKB/Swiss-Prot.
∗Validated by multiple, independent submissions to the refSNP cluster.
∗∗Validated by frequency or genotype data: minor alleles observed in at least two chromosomes.
#Validated by the 1000 Genomes Project, http://www.1000genomes.org/.4 Molecular Biology International
R53C; A60T
C65R
I135T
A336T
K21Q; R28H
V47F
D129Q
S131F
A133S
R201H
V211A
F218S
E246K
R257Q H315R
Y325C
SH3 C1 ATM RA Sarah
#
(Zinc ﬁnger (MOAP 1;
MST1/2)
Cdc20 association1-109 C19ORF5/MAP1S association120-340
∗∗ ∗ ∗
55PAGP 51-101 194-289 217-337 ETPDLS131QAE
60-104)
(TNF-R1
TRAIL-R1)
VRPVS175VPSSKKPPSL
14-3-3
14-3-3
σ, ε
∗D-boxes: 22RTPL, 77RKGL, 231RKFL, 257RKLL, 267RLRL, 317RQIL
#KEN-box: 284KEN
Figure 1: Schematic of RASSF1A with location of identiﬁed polymorphisms. Location of identiﬁed RASSF1A polymorphisms is indicated
with respect to amino acid location, changed amino acid, and exon location. A potential binding sequence to an SH3 domain has been
identiﬁed with a PxxP motif. The ATM phosphorylation site is underlined with surrounding residues shown. The docking sites for several
RASSF1A eﬀector proteins are shown including the location of potential D- and KEN-boxes for protein association (D1 to D6). The latter
boxes are thought to be important for associations with APC/cdc-20 [12]. The Ras association domain (RA) is present in RASSF1A but
has not been convincingly demonstrated to associate with the Ras family of oncogenes [10]. The SARAH domain modulates heterotypic
associations with the sterile-20-like kinases, MST1 and MST2 (adapted from El-Kalla et al. (2010)) [13] and Gordon and Baksh (2011) [10].
functions to stabilize tubulin both in interphase and in
mitosis even in the presence of the microtubule destabilizer,
nocodazole [13, 27, 33, 34]. To date, RASSF1A has not
been demonstrated to colocalize to actin or intermediate
ﬁlaments.RASSF1Aassociationsfunctiontostabilizetubulin
in a paclitaxel (taxol)-like manner [17, 27] especially during
mitosis allowing sister chromatid segregation. This function
is governed by associations with γ-tubulin at spindle poles
and centromeric areas during metaphase and anaphase and
near the microtubule organizing center (MTOC) where
microtubules emerge and nucleate [35–37]. If the micro-
tubule spindle complex is not properly formed, cell death
proceeds to prevent inheritable aneuploidy. In the absence
of cell death pathways chromosomal missegregation and
inheritable aneuploidy arise which can lead to malignancy.
Several of the eﬀects on microtubule biology have been
observed in mouse embryonic ﬁbroblasts (MEFs) obtained
from Rassf1a−/− mice developed by two separate groups [19,
38]. Rassf1a−/− mice are viable, fertile and retain expression
of isoform 1C. However, by 12–16 months of age they have
increased tumor incidence, especially in the breast, lung,
and immune system (gastrointestinal carcinomas and B-cell-
related lymphomas) [19, 38] .T h e s ed a t as u g g e s tat u m o r
suppressor function speciﬁc for the RASSF1A isoform. MEFs
obtained from Rassf1a−/− mice are more susceptible to
nocodazole-induced microtubule depolymerization suggest-
ing a protective eﬀect of RASSF1A on microtubule stability
similar to what has been observed using tissue culture
approaches [19].
It has now been demonstrated that RASSF1A dis-
ease associated polymorphisms may aﬀect the function of
RASSF1A as a microtubule stabilizer. It was demonstrated
that the S131F mutant of RASSF1A continued to maintain
the ability to promote tubulin stability as determined by
immunoﬂuorescence microscopy and acetylation status of
tubulin [17]. Furthermore, it was demonstrated by Vos et al.
[17]thatRASSF1Ccouldnotfunctioninasimilarmannerto
RASSF1A to stabilize tubulin. This provided one of the ﬁrst
evidences for diﬀerential function for these two prominent
isoforms of the RASSF1 loci. A comprehensive analysis of
several other RASSF1A polymorphisms was carried out by
Liu et al. [39]. They demonstrated that polymorphisms
around the ATM phosphorylation site (A133S, S131F, and
I135T)maintainedthemicrotubuleappearanceofRASSF1A.
A second comprehensive study revealed that the C65R and
R257Q polymorphisms of RASSF1A resulted in “atypical
localizations”ofRASSF1Aawayfromamicrotubularappear-
ance [27]. Furthermore, both C65R (a residue within the
C1 domain) and R257Q (a residue within the RA domain)
promoted enhanced BrdU incorporation into NCI-H1299Molecular Biology International 5
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Figure 2: Microtubule localization of RASSF1A. GFP-RASSF1A was expressed in U2OS osteosarcoma cells (a and b) and costained with
DAPI to reveal the nucleus (a and b) and with mitotracker red to reveal mitochondrial localization (b). Areas of yellow reveal colocalization
and all images were acquired using confocal microscopy using a Zeiss system and a 63x oil immersion lens.
nonsmall cell lung cancer cells suggesting loss of tumor
suppressor function. Recently, we have also observed a
complete loss of the microtubule localization of RASSF1A in
the presence of a C65R change and “oncogenic” properties
of this polymorphism in a classical xenograft assay in
athymic mice [13]. The C65R polymorphism acquired a
nuclear localization for unexplained reasons and also failed
to stabilize tubulin in the presence of the microtubule
depolymerizing agent nocodazole [13]. It clearly lost the
tumor suppressor function of RASSF1A in a xenograft assay
and can robustly drive enhanced growth [13]. Similarly,
both the A133S and E246K mutants maintained microtubule
localization and lost tumor suppressor function but not to
the level of the C65R polymorphism (xenograft assays were
carried out in HCT116 colon cancer cells) [13]. We are
currently characterizing many of the other polymorphisms
in Table 1 for their ability to behave as tumor suppressor,
inhibit abnormal growth, and aﬀect microtubule stability
and protein interaction with established RASSF1A eﬀectors.
Interestingly, it has been reported that Epstein-Barr
virally encoded protein, latent membrane protein 1 (LMP1)
can function to transcriptionally decrease RASSF1A lev-
els and promote tubulin depolymerization and mitotic
instability in human epithelial cells (HeLa and HaCaT)
[40]. Punctuate structures of tubulin were observed in
the cytoplasm indicative of tubulin depolymerization [40].
Decreased RASSF1A levels resulted in increased phospho-
rylation of IκBα and elevated NFκB activity. Cause and
eﬀect of changes in NFκB activity were not fully elucidated.
However, we have evidence that the loss of RASSF1A can
lead to enhanced NFκB activity (El-Kalla et al., unpublished
observations) suggesting that the decreased expression of
RASSF1A induced by LMP1 production may have resulted
from the loss of the ability of RASSF1A to restrict NFκB
function.EPVinfectioniscloselyrelatedtotheappearanceof
nasopharyngealcancersandwespeculatethataprecondition
characterized by enhanced NFκB activity (and hence inﬂam-
mation) may promote tumorigenesis and the appearance
of nasopharyngeal cancers upon EBV infection. We are
currently exploring the role of RASSF1A as a molecular link
between inﬂammation and tumorigenesis.6 Molecular Biology International
4.RASSF1A:LinkingExtrinsicDeath Receptor
Stimulation to Bax Activation
Every cell has an inherent ability to die under abnormal
conditions. This ability has been programmed by nature
into every cell and follows a deﬁned series of events.
Apoptosis is critical for multiple physiological processes,
including organ formation, immune cell selection, and
inhibition of tumor formation [41]. Two types of signaling
pathways promote apoptosis using the mitochondria. The
“intrinsic” pathway is activated by noxious factors such as
DNA damage, unbalanced proliferative stimuli, and nutrient
or energy depletion. Components of intrinsic-dependent
apoptosis are still unclear, although Bcl-2-homlogy domain
3 (BH3) proteins are required. In contrast, the “extrinsic”
pathway is stimulated by speciﬁc death receptors (e.g.,
TNFα receptor R1 (TNF-R1), TNFα-related apoptosis-
inducing ligand receptor (TRAIL-R1) or Fas (CD95)) [42–
44]. Molecular mechanisms modulating programmed cell
death (apoptosis) impinge on growth and immune cell
function. We speculate that these cellular processes may be
regulated in part by tumor suppressor pathways, pathways
frequentlyinactivatedinseveraldiseasestates(suchascancer
and autoimmune/inﬂammatory disorders).
RASSF1A is one element involved in death receptor-
dependent cell death that is epigenetic-silenced in numerous
cancers.Inthemajority ofthesestudies,RASSF1Aepigenetic
silencing strongly correlates with the epigenetic silencing of
three other genes—p16INK4a, death associated protein kinase
(DAPK), and caspase 8 [45–48]. Two of these genes are
involved in proapoptotic pathways, DAPK and caspase-8
[43, 49, 50]. DAPK is a unique calcium/calmodulin activated
serine/threonine kinase involved in several cell death-related
signaling pathways including tumor necrosis factor α recep-
tor 1 (TNF-R1) cell death and autophagy [50, 51]. It is a
t u m o rs u p p r e s s o rp r o t e i n[ 50] that has also been demon-
strated to be involved in associations with and the regulation
of pyruvate kinase, a key glycolytic enzyme that may be
inﬂuential in the link between metabolism and cancer [52].
We have evidence to demonstrate association of RASSF1A
and DAPK (Baksh et al., unpublished observations) and
RASSF1A has two potential phosphorylation sites for DAPK
within the RA domain at 193GRGTSVRRRTSFYLPK [53].
Curiously, these sites have also been demonstrated to be
sites for protein kinase C [54] and aurora kinases [55]. In
the presence of S197A or S203A mutant of RASSF1A, PKC
failed to phosphorylate RASSF1A resulting in the loss of
microtubule organization in COS-7 cells. Similarly, Aurora
B kinase failed to phosphorylate RASSF1A in the presence of
S203A resulting in a failed cytokinesis [55]. It remains to be
determined the physiological importance of these potential
DAPK phosphorylation sites.
Caspase 8 is cysteine-dependent aspartate-directed pro-
tease and an initiator caspase, and targeted activation of
caspase 8 is driven by the disc inducing signaling complex
(DISC) [43, 49]. DISC-dependent activation of caspase 8
triggers a series of events resulting in the cleavage of Bid and
insertion of Bid on the outer mitochondrial membrane, the
release of small molecules (such as cytochrome c) from the
mitochondria into the cytosol, and the activation of down-
stream eﬀector caspases (such as caspase-3) [56]. Intrinsic
pathway stimulation also leads to cytochrome c release and
eﬀector caspase activation. Once activated, eﬀector caspases
cleave several proteins (such as poly(ADP-ribose) poly-
merase (PARP)) and activate speciﬁc DNA endonucleases
resulting in nuclear and cytoplasmic breakdown [57].
Our research group was the ﬁrst to deﬁne and continues
to deﬁne some of the molecular mechanisms of death
receptor-dependent apoptotic regulation by RASSF1A [20,
58, 59]. Ectopic expression of RASSF1A (but not RASSF1C)
speciﬁcally enhanced death receptor-evoked apoptosis stim-
ulated by TNFα that does not require caspase 8 activ-
ity or Bid cleavage [20, 58]. We have also shown that
RASSF1A does not inﬂuence the intrinsic pathway of cell
death [58]. Furthermore, we demonstrated that microtubule
localizationwasrequiredforassociationwithdeathreceptors
and for the role of RASSF1A in apoptosis [13, 20]. In
contrast, RASSF1A knockdown cells (by RNA interference)
and Rassf1a−/− knockout mouse embryonic ﬁbroblasts
(MEFs) have signiﬁcantly reduced caspase activity, defective
cytochrome c release and Bax translocation (but not Bid
cleavage), and impaired death receptor-dependent apoptosis
[58]. These data suggest a direct link of death receptor
activation of Bax through RASSF1A. Our current model
of RASSF1A-mediated cell death is described in Figure 3.
Death receptor stimulation functions to bring RASSF1A
(and not RASSF1C or RASSF5A/Nore1A) and modulator
of apoptosis 1 (MOAP-1) to TNF-R1 in order to promote
a more “open” MOAP-1 to subsequently associate and
promote Bax conformational change and translocation to
the mitochondria to activate cell death (Figure 3)[ 20, 58–
60]. We have evidence that the 14-3-3 may keep RASSF1A in
check and inhibit it from promoting cell death or associating
with other unexplored signaling components [59]. We are
currently characterizing the primary and secondary signals
required for MOAP-1 induced Bax conformational change
and the apoptotic regulation of MOAP-1 by ubiquitination
(Law et al., unpublished observations).
To date, very little is known about the cell death
properties of numerous RASSF1A polymorphisms. Dallol
et al. demonstrated that both C65R and R257Q promoted
enhanced BrdU incorporation into NCI-H1299 non-small
cell lung cancer cells suggesting loss of tumor suppressor
function and possible loss of cell death properties [27]. We
have observed partial activation of apoptosis in the presence
of several RASSF1A polymorphisms (such as C65R, A133S,
I135T, and A336T) suggesting importance to death receptor-
dependent apoptosis via ATM site and SARAH domain
associations (El-Kalla et al., unpublished observations).
Further analysis is warranted to explore how RASSF1A poly-
morphisms may aﬀect death receptor-dependent apoptosis.
Although not discussed in great detail here, RASSF1A
can also promote cell death utilizing the autophagic protein,
C19ORF5/MAP1S, [27, 33, 61] the Hippo pathway com-
ponents MST1/2 and possibly Salvador [14, 62], and, in
melanoma cells, inﬂuence Bcl-2 levels and activate apoptosis
signal regulating kinase 1 (ASK-1) [63]. Min et al. [33]
demonstrated that the ability of RASSF1A to eﬃcientlyMolecular Biology International 7
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Figure 3: Model for the RASSF1A/MOAP-1 proapoptotic pathway. Death receptor-induced cell death (TNFα is used as an example) can
result in the recruitment of protein complexes to activate Bax and promote apoptosis. Basally, RASSF1A is kept complexed with 14-3-3
by GSK-3β phosphorylation in order to prevent unwanted recruitment of RASSF1A to death receptor and uncontrolled stimulation of
Bax and apoptosis. Once a death receptor stimuli have been received (TNFα as shown above), the TNF-R1/MOAP-1/RASSF1A complex
promotes the “open” form of MOAP-1 to associate with Bax. This in turn results in Bax conformational change and recruitment to the
mitochondria to initiate cell death. Following release from TNF-R1/MOAP-1 complex, RASSF1A may reassociate with 14-3-3 to prevent
continued stimulation of this cell death pathway (unpublished observations). Please see text for further details.
inhibit APC/cdc20 activity during mitosis (please see next
section) is dependent on the recruitment of RASSF1A to
spindle poles via C19ORF5/MAP1S. C19ORF5/MAP1S was
also shown to regulate mitotic progression by stabilizing
mitotic cyclins in a RASSF1A-dependent manner. Recently,
C19ORF5/MAP1S was demonstrated by Lui et al. [61]t o
associate with a component of the autophagosome, LC3,
and the mitochondria-associatedv leucine-rich PPR-motif
containing protein (LRPPRC) protein. These associations
suggest that C19ORF5/MAP1S may serve as a potential link
between autophagic cell death, mitochondria, and micro-
tubules and appears to require RASSF1A. It will be essential
to determine associations of RASSF1A polymorphisms with
key cell death mediators, such as MOAP-1, TNF-R1, DAPK,
C19ORF5/MAP1S, and MST1/2 in order to ascertain their
importance in inﬂuencing the tumor suppressor function
of RASSF1A. A detailed discussion about the Hippo and
RASSF1A/MOAP-1pathwaysofcelldeathispresentedinthis
special review.
5. CellCycle Control Pathways
Inﬂuenced by RASSF1A
As mentioned previously, RASSF1A is a microtubule binding
protein that colocalizes with α-a n dβ-tubulin, and with γ-
t u b u l i no nc e n t r o m e r e s[ 35–37]. RASSF1A is thought be an
important component of mitotic spindles and can inﬂuence
the separation of sister chromatids at the metaphase plate.
This observation has held true ﬁve years later and reinforced
the ﬁndings of Song et al. [64] of the possible involvement
of RASSF1A in cell cycle control. Although, very limited
knowledge of the cell cycle eﬀects of polymorphic forms of
RASSF1A are known, several lines of evidence do suggest a
role in cell cycle control. In 2004, RASSF1A was identiﬁed as
aninteractingproteinwiththeanaphasepromoting complex
(APC)/cdc20 and prevented the ability of APC/cdc20 to
degrade cyclins A and B in order to exit mitosis [64]. In the
absence of RASSF1A, cyclins A and B were rapidly degraded
due to increased ubiquitination of the cyclins to allow exit
from mitosis.8 Molecular Biology International
Whitehurst et al. [65] supported this role for RASSF1A
and further identiﬁed β-TrCP as associating with RASSF1A
and functioning to restrict the role of APC-cdc20 in mitotic
progression. β-TrCP is an IκBα E3 ligaseand negative regula-
toroftheβ-catenin/WNTsignalingpathway.AlthoughLiuet
al.couldnotﬁndevidenceforaRASSF1A-APC/cdc20associ-
ation[66],theinﬂuenceofRASSF1AonAPC/cdc20wasonce
again demonstrated by Chow et al. in 2011 [67]. They not
only demonstrated an association with APC/cdc20, but also
clearly showed that a “RASSF1A-APC/cdc20 circuitry” was
inplaceinHeLacellstoregulatemitosis.RASSF1Aassociates
with APC/cdc20 via two D boxes at the N-termini (DB1 and
DB2)andkeepsitinhibiteduntilthereismitoticactivationof
the serine/threonine kinases Aurora A/B. Phosphorylation of
RASSF1AbyAuroraA/BonT202orS203subsequentlylabels
RASSF1A as a target to the E3-ubiquitin ligase activity of
APC, ensuring that mitosis proceeds by degrading RASSF1A
and suppressing its mitotic inhibitor function [12]. They
speculate that this occurs before spindle body formation and
sister chromatid separation. Their results are intriguing and
reveal the complex signaling world that RASSF1A is part of.
Beyond a RASSF1A-APC/cdc20 molecular control of
mitosis, research has continued into a potential role of
RASSF1A during cell cycle progression. This has led to
several observations suggesting RASSF1A G1/S regulation
of cyclin D1 [63, 65, 68]i nm e l a n o m aa n dH e L ac e l l s
(resp.),interactionwiththetranscriptionalregulatorp120E4F
atthe G1/S phasetransition resulting in inhibition ofpassage
from G1 [69], DNA damage control regulation by ATM and
by the DNA damage binding protein 1 (DDB1) that can
associate with RASSF1A linking to the E3-ligase cullin 4A
during mitosis [70]. The p120E4F transcription factor was
determined to be involved in inhibiting the transcription of
cyclin A, resulting in the failure of cyclin A to associate with
CDK2 to allow for progression through S phase. RASSF1A
cooperates with p120E4F to repress cyclin A expression by
enhancing its binding at the promoter region [69]. ATM and
DDB1 are important DNA damage control elements during
ultraviolet and gamma irradiation which have evolved to
repair damage DNA and will be discussed elsewhere in this
special RASSF issue.
Shivakumar et al. revealed that in both H1299 non-
small cell lung cancer and in the human mammary epithelial
telomerase immortalized (HME50-hTERT) cell line, over-
expression of RASSF1A wild-type expression construct can
reduce BrDU accumulation and cyclin D1 expression [68].
The ability of RASSF1A to inhibit growth, and cyclin D1
expression was lost in the presence of the A133S and S131F
ATM site mutants of RASSF1A suggesting an important
role in tumor suppression [68]. Other polymorphic forms
of RASSF1A have not been explored with respect to their
abilities to regulate mitosis. What these studies reveal is
how highly regulated RASSF1A is, not only in interphase
cells, but especially in cells undergoing active cell division.
It can then be appreciated how devastating the functional
consequence of the loss of RASSF1A would be resulting in
an unregulated and unwanted increase in mitotic cyclins,
accelerated mitosis, enhanced growth and tumor formation.
It would be interesting to speculate that they may result
in the loss of the ability of RASSF1A to properly regulate
mitosis and inhibit unwanted proliferation. It is imperative
that we understand completely how polymorphic changes in
RASSF1A may inﬂuence the important role of RASSF1A in
mitosis and other biological pathways (Figure 4).
6. The DNA Damage Connection
One of the ﬁrst motifs identiﬁed on RASSF1A was the
phosphorylation site for the DNA damage serine/threonine
kinase Ataxia telangiectasia mutated (ATM). ATM is usually
a c t i v a t e da n dr e c r u i t e di nr e s p o n s et od o u b l es t r a n db r e a k s .
It is part of a DNA damage checkpoint that ensures that
damaged DNA is repaired in a timely and eﬃcient manner.
RASSF1A has been shown by several groups to be phospho-
rylatedbyATMandtheATMsitepolymorphismsarepresent
in several cancer types [71]. Although not currently well
deﬁned, RASSF1A is believed to have an important role in
DNA damage controlas evidencedby associations withxero-
derma pigmentosum complementation group A (XPA) [72]
and phosphoregulation by ATM [71, 73] .X P Ai si n v o l v e d
in nucleotide excision repair and association with RASSF1A
has only been identiﬁed in a yeast two-hybrid screen [24].
Hamilton et al. [71] elucidated a novel pathway linking
ATM-dependent phosphorylation of RASSF1A in response
to gamma irradiation on serine-131 followed by MST/LATS
activation resulting in Yes associated protein (YAP)/p73-
dependent transcriptional program to promote cell death.
The S131F mutant of RASSF1A lacked the ability to carry
out the transactivation of YAP/p73. Curiously, RASSF1C has
beendemonstratedtobeconstitutivelyanchoredtothedeath
domain-associated protein (DAXX) in the nucleus and is
released upon UV-induced DNA damage [16]. Localization
with DAXX occurs on promyelocytic leukaemia-nuclear
bodies (PML-NBs). DNA damage promotes the degradation
and ubiquitination of DAXX, release of RASSF1C to allow
the nucleocytoplasmic shuttling of RASSF1C to cytoplasmic
microtubules, and the activation of the SAPK/JNK pathway
in HeLa cells. RASSF1A was shown to only associate weakly
with DAXX suggesting a speciﬁc role for RASSF1C [16].
Recently, it was demonstrated that the E3 ligase, Mule, can
ubiquitinate RASSF1C under normal conditions, and both
Mule and β-TrCP can ubiquitinate RASSF1C under UV
exposure [74]. These studies and others have continued
to demonstrate the diverse role that the splice variants of
RASSF1mayfunctioninbiology.Adetaileddiscussionabout
the role of RASSF1A during DNA damage repair will be
presented in this special review.
7. RASSF1C: The Other RASSF1 Isoform
Very little is known about the biological role for the other
major splice variant of the RASSF1 gene family. Several
lines of evidence suggest that RASSF1C may be a tumor
suppressorgenein prostateand renalcarcinoma cellsbutnot
in lung cancer cells [75]. In fact, it has been demonstrated
by Amaar et al. that the loss of RASSF1C actually results
in the loss of proliferation of lung and breast cancer cells
suggesting a prosurvival (not tumor suppressor) role forMolecular Biology International 9
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Figure 4: Identiﬁed biological roles for RASSF1A polymorphisms. Several polymorphisms have been identiﬁed for RASSF1A over the past
decade since it was ﬁrst cloned. Biological analyses of the in vivo role have identiﬁed the importance of RASSF1A over numerous pathways.
This ﬁgure summarizes what is known about RASSF1A polymorphisms. ∗denotes a nonpolymorphic but mutational change. This change
does not naturally exist in the cancer patient population to our knowledge.
RASSF1C [76, 77]. Furthermore, RASSF1C can associate
with the E3 ligase β-TrCP via the SS18GYXS19 motif (where
X is any amino acid and numbers correspond to amino
acid sequence in RASSF1C) at the N-terminus (i.e., not
present in RASSF1A) [78] and promote the accumulation
and transcriptional activation of β-catenin [78]. Activation
of β-catenin would result in enhanced proliferation by
transcriptional upregulation of genes such as cyclin D1, Myc,
and TCF-1. Thus, either the lack of RASSF1A expression or
theoverexpression ofRASSF1Cperturbs β-TrCPE3ligase/β-
catenin homeostasis and WNT signaling pathways.
UnlikeRASSF1A,RASSF1Chasnotbeenfoundtobesig-
niﬁcantly epigenetically silenced in cancer. Polymorphisms
to RASSF1C have not been uncovered yet, but a C61F
mutation in RASSF1C (equivalent to the S131F mutation
in RASSF1A) resulted in the failure of RASSF1C to protect
microtubules against nocodazole-induced depolymerization
[17]. This would again suggest importance of serine residue
within the ATM site found on both RASSF1A and 1C.
Recently,ithasbeensuggestedthatapossiblepathogenicrole
for RASSF1C in cancer may exist as its expression was more
thaneleven-foldgreaterinpancreaticendocrinetumorsthan
in normal tissue [79]. It remains to be determined the exact
biological role for RASSF1C, but the ability of RASSF1C to
function as a tumor suppressor is cell speciﬁc and remains to
be further investigated and conﬁrmed.
8. The Futureof Understanding
RASSF Polymorphisms
Knudson stated in 1971 that cancer is the result of accu-
mulated mutations to the DNA of cells and that multiple
“hits” to DNA were necessary to cause cancer [80]. It
is generally known that the loss of function in a tumor
suppressor protein typically requires the inactivation of both
alleles of its gene in contrast to proto-oncogenes which
promote tumorigenesis due to dominant acting mutations
aﬀecting one gene copy. Similar to what Knudson discovered
for retinoblastoma, the RASSF1A tumor suppressor may
become inactivated by the epigenetic loss by promoter
speciﬁc methylation of both allele or by a combination
of epigenetic silencing and loss of function polymorphic
changes. Most cancers investigated to date have >50% of
the disease population containing epigenetic silencing of
RASSF1A [11, 81]. However, numerous cancers such as
cervical, head and neck, myeloma, and leukemia have <25%
of the disease population containing epigenetic silencing of
RASSF1A. It may be speculated that polymorphic changes to
RASSF1A may exist in the latter patients that, in agreement
with the Knudson two hit hypothesis, resulting in the loss
of function of the RASSF1A tumor suppressor and causing
cancer. A systematic and functional analysis of RASSF1A
polymorphism is therefore necessary to allow physicians
to carry out personalized medicine on patients harboring
polymorphic changes to RASSF1A.
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